AR097932A1 - Antagonista del receptor de somatostatina del subtipo 5 (sstr5) - Google Patents
Antagonista del receptor de somatostatina del subtipo 5 (sstr5)Info
- Publication number
- AR097932A1 AR097932A1 ARP140103713A ARP140103713A AR097932A1 AR 097932 A1 AR097932 A1 AR 097932A1 AR P140103713 A ARP140103713 A AR P140103713A AR P140103713 A ARP140103713 A AR P140103713A AR 097932 A1 AR097932 A1 AR 097932A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- compound
- ring
- alkyl group
- salt
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 101000829153 Homo sapiens Somatostatin receptor type 5 Proteins 0.000 abstract 1
- 102100023806 Somatostatin receptor type 5 Human genes 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo P representa un anillo heterocíclico aromático de 6 miembros; el anillo A representa un anillo heterocíclico saturado que contiene nitrógeno de 4 a 7 miembros opcionalmente sustituido; el anillo B representa un anillo de benceno opcionalmente sustituido o un anillo heterocíclico opcionalmente sustituido; R¹ y R² representan cada uno de forma independiente un átomo de hidrógeno, un grupo C₁₋₆ alquilo opcionalmente sustituido, un grupo C₃₋₁₀ cicloalquilo o CO₂R (en donde R representa un átomo de hidrógeno o un grupo C₁₋₆ alquilo opcionalmente sustituido); uno de R¹ y R² es CO₂R; W representa un grupo C₁₋₂ alquileno opcionalmente sustituido con un grupo C₁₋₆ alquilo; y R³, R⁴, R⁵ y R⁶ representan cada uno de forma independiente un átomo de hidrógeno o un grupo C₁₋₆ alquilo; o una sal de él.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013209826 | 2013-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097932A1 true AR097932A1 (es) | 2016-04-20 |
Family
ID=51842719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103713A AR097932A1 (es) | 2013-10-07 | 2014-10-06 | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9353108B2 (es) |
| EP (1) | EP3055309B1 (es) |
| JP (1) | JP6411520B2 (es) |
| CN (1) | CN105612158B (es) |
| AR (1) | AR097932A1 (es) |
| BR (1) | BR112016007620B1 (es) |
| CA (1) | CA2926544C (es) |
| CY (1) | CY1121163T1 (es) |
| DK (1) | DK3055309T3 (es) |
| ES (1) | ES2687102T3 (es) |
| HR (1) | HRP20181372T1 (es) |
| HU (1) | HUE039386T2 (es) |
| JO (1) | JO3442B1 (es) |
| LT (1) | LT3055309T (es) |
| PL (1) | PL3055309T3 (es) |
| PT (1) | PT3055309T (es) |
| RS (1) | RS57743B1 (es) |
| RU (1) | RU2671958C2 (es) |
| SI (1) | SI3055309T1 (es) |
| TR (1) | TR201810506T4 (es) |
| TW (1) | TWI648276B (es) |
| UY (1) | UY35774A (es) |
| WO (1) | WO2015052910A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6247697B2 (ja) * | 2013-03-14 | 2017-12-13 | 武田薬品工業株式会社 | スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用 |
| EP3227282B1 (en) * | 2014-12-02 | 2019-04-03 | F.Hoffmann-La Roche Ag | Novel piperidine derivatives |
| TW201712012A (zh) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物 |
| BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
| TW202207929A (zh) * | 2020-05-13 | 2022-03-01 | 日商思可海雅藥品股份有限公司 | 膽道系疾病的診斷輔助、預防或治療劑 |
| BR112022023359A2 (pt) | 2020-05-19 | 2023-04-18 | Kallyope Inc | Ativadores de ampk |
| EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
| CN116354961A (zh) * | 2021-12-27 | 2023-06-30 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其药物组合物及用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| EP1432708B1 (en) | 2001-09-24 | 2005-11-30 | Bayer Pharmaceuticals Corporation | Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| RU2004112771A (ru) * | 2001-09-26 | 2005-10-10 | Байер Фармасьютикалс Корпорейшн (US) | Производные 1, 8-нафтиридина как противодиабетические средства |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| NZ540381A (en) | 2002-11-01 | 2007-11-30 | Takeda Pharmaceutical | 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy |
| WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
| US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
| JP2007513082A (ja) | 2003-11-10 | 2007-05-24 | シエーリング アクチエンゲゼルシャフト | Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物 |
| CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
| BRPI0418148A (pt) | 2003-12-25 | 2007-04-17 | Takeda Pharmaceutical | composto, prodroga de um composto, modulador da função do receptor gpr40, agente farmacêutico, uso de um composto e métodos de modificação de uma função do receptor gpr40 em um mamìfero, de profilaxia ou tratamento de diabetes em um mamìfero e de produção de um composto |
| JP4855777B2 (ja) | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | フェニルプロパン酸誘導体 |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| WO2005095338A1 (ja) | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| JPWO2007013694A1 (ja) | 2005-07-29 | 2009-02-12 | 武田薬品工業株式会社 | フェノキシアルカン酸化合物 |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| CA2617969A1 (en) | 2005-08-10 | 2007-02-15 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| WO2008019967A2 (en) * | 2006-08-15 | 2008-02-21 | F. Hoffmann-La Roche Ag | Phenyl, pyridine and quinoline derivatives |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| NZ576570A (en) | 2006-10-19 | 2010-11-26 | Takeda Pharmaceutical | 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| US7862825B2 (en) | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| US7799806B2 (en) * | 2007-04-04 | 2010-09-21 | Hoffmann-La Roche Inc. | Substituted n-benzyl piperidines as somatostatin receptor modulators |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| US20080306116A1 (en) | 2007-06-08 | 2008-12-11 | Christ Andreas D | Aryloxazole, aryloxadiazole and benzimidazole derivatives |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| EP2427465A1 (en) | 2009-05-07 | 2012-03-14 | Merck Sharp & Dohme Corp. | Substituted spirocyclic amines useful as antidiabetic compounds |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| AU2011333472A1 (en) | 2010-11-26 | 2013-06-06 | Lupin Limited | Bicyclic GPR119 modulators |
| JP6247697B2 (ja) | 2013-03-14 | 2017-12-13 | 武田薬品工業株式会社 | スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用 |
| AR098215A1 (es) | 2013-10-29 | 2016-05-18 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
-
2014
- 2014-10-02 JO JOP/2014/0283A patent/JO3442B1/ar active
- 2014-10-03 US US14/505,907 patent/US9353108B2/en active Active
- 2014-10-06 PT PT14790746T patent/PT3055309T/pt unknown
- 2014-10-06 AR ARP140103713A patent/AR097932A1/es active IP Right Grant
- 2014-10-06 WO PCT/JP2014/005075 patent/WO2015052910A1/en active Application Filing
- 2014-10-06 BR BR112016007620-6A patent/BR112016007620B1/pt active IP Right Grant
- 2014-10-06 LT LTEP14790746.3T patent/LT3055309T/lt unknown
- 2014-10-06 TW TW103134715A patent/TWI648276B/zh active
- 2014-10-06 CA CA2926544A patent/CA2926544C/en active Active
- 2014-10-06 TR TR2018/10506T patent/TR201810506T4/tr unknown
- 2014-10-06 EP EP14790746.3A patent/EP3055309B1/en active Active
- 2014-10-06 ES ES14790746.3T patent/ES2687102T3/es active Active
- 2014-10-06 HU HUE14790746A patent/HUE039386T2/hu unknown
- 2014-10-06 RU RU2016117732A patent/RU2671958C2/ru active
- 2014-10-06 UY UY0001035774A patent/UY35774A/es not_active Application Discontinuation
- 2014-10-06 CN CN201480055324.3A patent/CN105612158B/zh active Active
- 2014-10-06 PL PL14790746T patent/PL3055309T3/pl unknown
- 2014-10-06 RS RS20181007A patent/RS57743B1/sr unknown
- 2014-10-06 JP JP2016546198A patent/JP6411520B2/ja active Active
- 2014-10-06 DK DK14790746.3T patent/DK3055309T3/en active
- 2014-10-06 SI SI201430838T patent/SI3055309T1/sl unknown
-
2016
- 2016-04-27 US US15/139,531 patent/US9751878B2/en active Active
-
2018
- 2018-08-27 HR HRP20181372TT patent/HRP20181372T1/hr unknown
- 2018-09-04 CY CY20181100912T patent/CY1121163T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105612158A (zh) | 2016-05-25 |
| BR112016007620B1 (pt) | 2020-05-26 |
| RS57743B1 (sr) | 2018-12-31 |
| TWI648276B (zh) | 2019-01-21 |
| JP6411520B2 (ja) | 2018-10-24 |
| EP3055309A1 (en) | 2016-08-17 |
| DK3055309T3 (en) | 2018-08-27 |
| PT3055309T (pt) | 2018-10-01 |
| US20150099777A1 (en) | 2015-04-09 |
| RU2671958C2 (ru) | 2018-11-08 |
| EP3055309B1 (en) | 2018-06-13 |
| TW201536784A (zh) | 2015-10-01 |
| US9353108B2 (en) | 2016-05-31 |
| WO2015052910A1 (en) | 2015-04-16 |
| ES2687102T3 (es) | 2018-10-23 |
| CA2926544A1 (en) | 2015-04-16 |
| HUE039386T2 (hu) | 2018-12-28 |
| US20160237087A1 (en) | 2016-08-18 |
| US9751878B2 (en) | 2017-09-05 |
| UY35774A (es) | 2015-05-29 |
| JP2016531950A (ja) | 2016-10-13 |
| BR112016007620A2 (pt) | 2017-08-01 |
| TR201810506T4 (tr) | 2018-08-27 |
| JO3442B1 (ar) | 2019-10-20 |
| PL3055309T3 (pl) | 2018-10-31 |
| CN105612158B (zh) | 2017-06-30 |
| RU2016117732A (ru) | 2017-11-15 |
| SI3055309T1 (sl) | 2018-10-30 |
| HRP20181372T1 (hr) | 2018-10-19 |
| LT3055309T (lt) | 2018-08-27 |
| CY1121163T1 (el) | 2020-05-29 |
| CA2926544C (en) | 2021-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097932A1 (es) | Antagonista del receptor de somatostatina del subtipo 5 (sstr5) | |
| AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR106605A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR100154A1 (es) | Compuesto heterocíclico que contiene nitrógeno | |
| ECSP15044389A (es) | Compuesto peptídico | |
| CO2019012271A2 (es) | Péptido activador de receptor de gip | |
| PE20151606A1 (es) | DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| PE20210162A1 (es) | Analogos de incretina y sus usos | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
| CO2018003367A2 (es) | Benzamidas sustituidas con isoxazolina y análogos como insecticidas | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR093825A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| AR128158A2 (es) | Compuesto heterocíclico | |
| AR089753A1 (es) | Derivados de amida heterociclicos como antagonistas del receptor p2x7 | |
| AR105549A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| BR112016027691A2 (pt) | Composto de tetra-hidropiridopirimidina e seus usos | |
| AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
| AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |